Melatonin has the potential to prevent occurrence of pneumonia and acute respiratory distress syndrome in patients diagnosed with COVID. This would mean decreasing mortality, decreasing or preventing hospital stays and decreasing the cost of care. This may also mean bringing our healthcare personnel and all essential workers back into the workforce sooner. From the moment this study receives approval, we estimate to have the final data in under 3 months. Are we going to find the right regulatory mentors to get the regulatory approval on time? We are a team of 4 physicians, 1 pharmacist and 1 biostatistician trying to make this happen. Wait, did I mention we have no money?
AMCOVID
Adjuvant Melatonin in COVID treatment
Log in or sign up for Devpost to join the conversation.